Compare BioNano Genomics Inc (BNGO) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Global X NASDAQ 100 Covered Call ETF trades at $18.26. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | QYLD | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $4.92 | $18.52 |
52-Week Low | $1.09 | $16.46 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
QYLD trades at $18.15, down 1.68% on the day, with technical indicators showing a neutral overall signal. The ETF's covered call strategy generates high monthly distributions but has historically lagged the Nasdaq-100's total return, with recent news highlighting NAV erosion despite consistent dividend payouts. Moving averages suggest a bullish trend while oscillators remain neutral, with all key support and resistance levels clustered around $18.
The outlook remains cautious as QYLD's high yield comes at the cost of capital appreciation potential. While attractive for income-focused investors, the strategy underperforms in strong bull markets. Key risks include capped upside and competitive pressure from lower-fee alternatives like GPIQ, requiring investors to prioritize income generation over growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
